Plain-English translation of NCT07495215 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a personalized mRNA vaccine designed specifically for you using genetic material from your own tumor. You would receive this vaccine alongside a standard immunotherapy drug (a PD-1 inhibitor) after your liver cancer surgery. The goal is to help your immune system recognize and destroy any remaining cancer cells that might otherwise cause the cancer to return.
Liver cancer often comes back after surgery, even when surgeons remove all visible tumors. This medication harnesses your body's own immune system to attack cancer cells before they can grow back, potentially offering a gentler approach with fewer severe side effects than traditional chemotherapy.
You likely qualify if…
You likely don't qualify if…
You would undergo genetic testing of your tumor tissue to design your personalized vaccine, which typically takes several weeks to prepare. Once ready, you would receive injections of the vaccine combined with the standard immunotherapy drug over multiple treatment cycles. The trial will monitor you closely with blood tests and imaging to track how well the treatment works and whether you experience any side effects, with the goal of following your health for at least 6 months to see if the cancer stays away.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China